Radiofrequency ablation (RFA) is
one of the most common minimally
invasive techniques for treating hepatocellular carcinoma (HCC), which
could destroy tumors through hyperthermia and generate massive tumor-associated
antigens (TAAs). However, residual malignant tissues or small satellite
lesions are hard to eliminate, generally resulting in metastases and
recurrence. Herein, an advanced in situ nanovaccine
formed by layered double hydroxides carrying cGAMP (STING agonist)
(LDHs-cGAMP) and adsorbed TAAs was designed to potentiate the RFA-induced
antitumor immune response. As-prepared LDHs-cGAMP could effectively
enter cancerous or immune cells, inducing a stronger type I interferon
(IFN-I) response. After further adsorption of TAAs, nanovaccine generated
sustained immune stimulation and efficiently promoted activation of
dendritic cells (DCs). Notably, infiltrations of cytotoxic lymphocytes
(CTLs) and activated DCs in tumor and lymph nodes were significantly
enhanced after nanovaccine treatment, which distinctly inhibited primary,
distant, and metastasis of liver cancer. Furthermore, such a nanovaccine
strategy greatly changed the tumor immune microenvironment and promoted
the response efficiency of anti-programmed death ligand 1 (αPD-L1)
immunotherapy, significantly arresting the poorly immunogenic hepa1–6
liver cancer progression. These findings demonstrate the potential
of nanovaccine as a booster for RFA in liver cancer therapy and provide
a promising in situ cancer vaccination strategy.